Depressive Disorder News and Research

RSS

Study reinforces efficacy of NeuroStar TMS Therapy System in patients with MDD

New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder during the acute phase of therapy, which were maintained through one year of treatment.

22 May 2013

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Journal provides guidance for clinicians on prescribing exercise for depressed patients

Exercise has been shown to be an effective treatment for major depressive disorder, both when used alone and in combination with other treatments.

13 May 2013

FDA: Migraine prevention medicines taken during pregnancy can impact children’s IQ

The U.S. Food and Drug Administration is alerting health care providers and patients that medications including and related to valproate sodium can cause decreased IQ scores in children whose mothers took the medication during pregnancy.

7 May 2013

Targacept reports net loss of $8.1 million in first quarter 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2013.

7 May 2013

NeuroSigma receives Class 2 medical device license for Monarch eTNS System from Health Canada

NeuroSigma, Inc., a California-based medical device company, today announced that it has received a Class 2 medical device license for its Monarch eTNS (external trigeminal nerve stimulation) System from Health Canada.

2 May 2013

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Neuralstem, Inc. announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

26 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

Junk DNA plays important role in brain development

Specific DNA once dismissed as junk plays an important role in brain development and might be involved in several devastating neurological diseases, UC San Francisco scientists have found.

16 Apr 2013

TBI can increase depression, personality impulsivity, PTSD in PNES patients

A new study by a Rhode Island Hospital researcher has found that traumatic brain injury (TBI) can significantly increase the odds of having major depression, personality impulsivity and post-traumatic stress disorder (PTSD) in patients with psychogenic nonepileptic seizures (PNES).

9 Apr 2013

Biological psychiatry shares progress in identifying genomic predictors of antidepressant response

Antidepressants are commonly prescribed for the treatment of depression, but many individuals do not experience symptom relief from treatment.

30 Mar 2013

Weill Cornell receives NIMH grant to discover novel biomarkers for chronic fatigue syndrome

Weill Cornell Medical College has been awarded more than $1.9 million by the National Institute of Mental Health of the National Institutes of Health to lead an innovative research study using advanced neuroimaging and clinical evaluations of patients with chronic fatigue syndrome (CFS).

8 Mar 2013

Family-focused therapy improves mood symptoms in youth at risk of bipolar disorder

A study published in the February 2013 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that children and adolescents with major depression or subthreshold forms of bipolar disorder - and who had at least one first-degree relative with bipolar disorder - responded better to a 12-session family-focused treatment than to a briefer educational treatment.

8 Mar 2013

Fractional anisotropy examines age-related decline in cerebral white matter in schizophrenia, MDD

Many lines of evidence indicate that schizophrenia is a disorder of neurodevelopment. For example, genes implicated in the heritable risk for schizophrenia are also implicated in the development of nerve cells and their connections.

7 Mar 2013

DBS helps anorexia patients achieve and maintain improvements in body weight, mood and anxiety

In a world first, a team of researchers at the Krembil Neuroscience Centre and the University Health Network have shown that Deep Brain Stimulation (DBS) in patients with chronic, severe and treatment-resistant Anorexia Nervosa (anorexia) helps some patients achieve and maintain improvements in body weight, mood, and anxiety.

6 Mar 2013

Depressive Disorder News and Research

Study reinforces efficacy of NeuroStar TMS Therapy System in patients with MDD

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Journal provides guidance for clinicians on prescribing exercise for depressed patients

FDA: Migraine prevention medicines taken during pregnancy can impact children’s IQ

Targacept reports net loss of $8.1 million in first quarter 2013

NeuroSigma receives Class 2 medical device license for Monarch eTNS System from Health Canada

Neuralstem gets approval from FDA for dosing cohort patients in NSI-189 Phase Ib in MDD treatment

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Junk DNA plays important role in brain development

TBI can increase depression, personality impulsivity, PTSD in PNES patients

Biological psychiatry shares progress in identifying genomic predictors of antidepressant response

Weill Cornell receives NIMH grant to discover novel biomarkers for chronic fatigue syndrome

Family-focused therapy improves mood symptoms in youth at risk of bipolar disorder

Fractional anisotropy examines age-related decline in cerebral white matter in schizophrenia, MDD

DBS helps anorexia patients achieve and maintain improvements in body weight, mood and anxiety

Misdiagnosed bipolar depression has subtle clinical features

Autism, ADHD, bipolar disorder, major depressive disorder and schizophrenia share common genetic risk factors

Patients with untreated depression are poorly protected by shingles vaccination

Depression reduces efficacy of shingles vaccine

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News